SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

EVAX

Evaxion
NEUTRAL
Impact 4/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Traders should monitor the AACR presentations for data depth, especially durability of immune response and biomarker correlation, which could influence sentiment. Participation in partnering events may lead to future collaboration announcements, potentially serving as a catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.78
T+0 close · Mar 17, 2026 · via day close
Latest settled
−4.50%
T+60 · $3.61
Vs SPY
−16.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $3.78entry
  2. T+1 · 8mo ago +5.82%α +6.09% · $4.00
  3. T+5 · 8mo ago −2.12%α −1.40% · $3.70
  4. T+20 · 7mo ago +9.52%α +3.48% · $4.14
  5. T+60 · 5mo ago −4.50%α −16.02% · $3.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced two abstracts accepted for presentation at the AACR Annual Meeting, featuring new biomarker and immunogenicity data for its personalized cancer vaccine EVX-01 in melanoma, and preclinical data on using its AI-Immunology™ platform to target glioblastoma. The company will also participate in an industry partnering event, signaling efforts to advance collaborations.

Key Facts

  • Two abstracts accepted for AACR 2026 presentation: one on EVX-01 clinical data in advanced melanoma, another on AI-identified neoantigens for glioblastoma.
  • EVX-01 data includes durable de novo T-cell responses from a Phase 2 trial combining the vaccine with KEYTRUDA® (pembrolizumab).
  • Glioblastoma research is preclinical, focusing on endogenous retrovirus (ERV)-derived neoantigens identified via AI-Immunology™.
  • Evaxion will attend the AACR Oncology Industry Partnering event, indicating business development activity.

Financial Impact

No financial impact disclosed; data is clinical and preclinical with no revenue or cost figures provided.

revenueepscashFlow

Risk Factors

  • No efficacy or survival data (e.g., overall survival, progression-free survival) disclosed in the release.
  • Glioblastoma program is preclinical; clinical applicability remains uncertain.
  • EVX-01 remains in Phase 2; no guarantee of regulatory or commercial success.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257673

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026